GlassScriptPhysician profile
Traysa S Smith
NPI 1881755817
$1,883.41
in general payments reported to CMS, 2019-2025
28 companies · $668 in 2025
The $668 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $256 · 2023: $260 · 2024: $188 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $301.77 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $176.30 | 2021-2024 | |
| Organon LLC | $157.23 | 2021-2025 | Nexplanon |
| Evofem Biosciences, INC. | $147.68 | 2021-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $122.85 | 2021-2025 | |
| Biogen, INC. | $119.12 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $110.27 | 2024-2025 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $101.14 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $100.68 | 2025 | Myosure Tissue Removal Device |
| Coloplast Corp | $78.21 | 2022-2025 | |
| Coopersurgical, INC. | $46.80 | 2025 | Paragard T 380a |
| Pacira Pharmaceuticals Incorporated | $41.57 | 2025 | Exparel |
| Shield Therapeutics INC | $41.17 | 2023-2025 | Accrufer |
| Agile Therapeutics, INC. | $38.76 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $38.52 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $31.48 | 2025 | Fibryga |
| Sanofi Pasteur INC. | $28.99 | 2025 | |
| Avion Pharmaceuticals | $27.83 | 2021-2022 | |
| Therapeuticsmd, INC. | $22.62 | 2021 | |
| Becton, Dickinson and Company | $20.72 | 2024 | Bd Surepath Collection Vial |
| Daiichi Sankyo INC. | $19.95 | 2022 | |
| Urovant Sciences INC | $18.75 | 2022 | |
| Eisai INC. | $18.60 | 2024 | |
| Pfizer INC. | $17.05 | 2022 | |
| Mayne Pharma Commercial LLC | $15.02 | 2025 | |
| Myovant Sciences INC. | $14.75 | 2021 | |
| Aspira Women'S Health INC | $13.38 | 2021 | |
| Axonics, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traysa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.